Commercial License Grants Sample Clauses

Commercial License Grants. 6.2.1 Subject to Section 5.3 and the other terms and conditions of this Agreement, Rigel hereby grants to Novartis and its Affiliates an exclusive license, with the right to grant sublicenses, under the Rigel Technology and Rigel's interest in the Project Technology to make, have made, use, import, offer for sale and sell Products.
Sample 1Sample 2Sample 3See All (4)
AutoNDA by SimpleDocs
Commercial License Grants. Subject to the terms and conditions of this Agreement, Versicor hereby grants to Novartis and its Affiliates an exclusive, royalty-bearing license in the Territory, with the right to sublicense pursuant to Section 9.4, under Versicor Patent Rights and Versicor's interest in Joint Patent Rights and Versicor's Know-How (pursuant to this Agreement) to develop, make, have made, use, sell, offer for sale and import Products in the Field of Use, subject to Versicor's right to co-promote the Co-Promotion Option Products in the U.S. and Canada in accordance with Article 5 hereof.
Sample 1Sample 2
Commercial License Grants. For each Commercial Target which ONCOMED has requested to be the subject of a Commercial Therapeutic License and which has been the subject of a positive License Response in accordance with Section 4.3(b): MORPHOSYS hereby grants to ONCOMED, under MORPHOSYS Patent Rights and MORPHOSYS Know-How: a worldwide, exclusive, royalty-bearing license (with the [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. right to grant sublicenses), to develop, make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, distribute, have distributed, import, have imported, export and have exported Licensed Therapeutic Products within the Field in the Territory (“Commercial Therapeutic License”). Together with any Commercial Therapeutic License granted hereunder, to the extent [***] MORPHOSYS grants to ONCOMED [***] a nonexclusive, non-royalty bearing license to make, have made, use and have used HuCAL Antibodies directed against such Commercial Target for clinical Monitoring for the clinical development of [***] Licensed Therapeutic Products directed against such Commercial Target (“Clinical Monitoring License”), [***] For purposes of clarification, ONCOMED shall not have the right to commercialize or sell, have sold, offer for sale, or have offered for sale a HuCAL Antibody for Clinical Monitoring or any other diagnostic purposes under the Clinical Monitoring License. Unless terminated as permitted under this Agreement, such Commercial Therapeutic License shall last until such time as no royalty on the Net Sales of Licensed Therapeutic Products covered by the Commercial Therapeutic License is due to MORPHOSYS, as provided under Section 6.3. Thereafter, the Commercial Therapeutic License shall convert to a fully paid-up non-exclusive license to develop, make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, distribute, have distributed, import, have imported, export and have exported Licensed Therapeutic Products within the Field in the Territory.
Sample 1Sample 2
Commercial License Grants. 14 6.3 License to Rigel of Improvements to Rigel Core Technology.......14 6.4 Option for License for Rigel Lead Compound......................14
Sample 1Sample 2

Related to Commercial License Grants

  • Commercial License Subject to the terms and conditions of this Agreement, CytomX hereby grants to ImmunoGen and its Affiliates an exclusive (even as to CytomX), non-transferable (except as expressly permitted in this Agreement), royalty-bearing license, including the right to grant sublicenses as described in Section 3.1.2 hereof, under the Licensed Intellectual Property, to Develop, make, have made, use, sell, offer for sale, import and otherwise Commercialize Licensed Products in the Field in the Territory. ImmunoGen and its Affiliates shall have the right to engage one or more Affiliates or Third Parties (the latter being referred to herein as “Permitted Third Party Service Providers”) as subcontractors to perform designated functions in connection with its activities under this Agreement (including transferring Licensed Know-How and CytomX Proprietary Materials as may be necessary for such Permitted Third Party Service Providers to perform such designated functions); provided that (a) ImmunoGen shall [***] and (b) ImmunoGen shall [***].

  • Initial License Fee In partial consideration for the exclusive license granted pursuant to Section 2.1 hereof, Licensee shall pay to Scripps a non-refundable license fee upon execution of this Agreement in the amount of 70,000 shares of Licensee common stock as specified in Exhibit D. The license fee described in this Section is consideration for the grant and continuation of the license hereunder, and Scripps shall have no obligation to return any portion of such license fee, notwithstanding any failure by Licensee to develop any Licensed Product or market any Licensed Product commercially, and notwithstanding the volume of sales of any such Licensed Product.

  • Additional Licenses For a period of five (5) years following the Distribution Date, in the event any member of the Honeywell Group, in Honeywell’s reasonable judgment, requires a license under any SpinCo IP in order to initiate and pursue any technical projects not covered by the licenses granted in Section 4.01(a), the Parties shall negotiate in good faith to license such SpinCo IP to the applicable member of the Honeywell Group on commercially reasonable terms. Notwithstanding anything to the contrary, if the Parties cannot reach agreement with respect to the terms of a license to SpinCo IP pursuant to the immediately preceding sentence, the applicable member of the Honeywell Group shall be permitted to challenge the validity or enforceability of such SpinCo IP (it being understood that such challenge is the sole remedy available to Honeywell in the event SpinCo does not grant such license, without regard to whether SpinCo has negotiated in good faith).

  • Exclusive License Grant Subject to the terms and conditions of this Agreement, Licensee hereby grants to Takeda an exclusive, sublicensable (subject to Section 3.3 (Sublicensing)), royalty-bearing right and license under the Licensee Technology and Licensee’s interest in the Joint Technology to Exploit the TAK-385 Licensed Compound and TAK-385 Licensed Products in the Field in the Takeda Territory.

  • License Grants Subject to the terms of this Agreement, M.I.T. hereby grants to COMPANY and its AFFILIATES for the TERM a royalty-bearing license under the PATENT RIGHTS to develop, make, have made, use, sell, offer to sell, lease, and import LICENSED PRODUCTS in the FIELD in the TERRITORY and to develop and perform LICENSED PROCESSES in the FIELD in the TERRITORY.

  • The License Licensor owns, operates and licenses a system designed to provide a distinctive, high quality hotel service to the public under the name "Homewood Suites" (the "SYSTEM"). High standards established by Licensor are the essence of the System. Future investments may be required of Licensee under this License Agreement ("AGREEMENT"). Licensee has independently investigated the risks of the business to be operated hereunder, including current and potential market conditions, competitive factors and risks, has read Licensor's "Franchise Offering Circular," and has made an independent evaluation of all such facts. Aware of the relevant facts, Licensee desires to enter into this Agreement in order to obtain a license to use the System in the operation of a Homewood Suites hotel located at 00000 X. XXXXX XXXXXX XXXXXXXXX, XXXXXX, XXXXXXXX 00000 (the "HOTEL") subject to the terms of this Agreement.

  • Non-Exclusive License Grant Subject to the terms and conditions of this Agreement, Takeda hereby grants to Licensee a non-exclusive, sublicensable (subject to Section 3.3 (Sublicensing)) right and license under the Takeda Technology and Takeda’s interest in the Joint Technology to: (a) Develop the TAK-385 Licensed Compound and TAK-385 Licensed Products in the Men’s Health Field in the Takeda Territory solely for the purpose of Exploiting such Licensed Products in the Field in the Licensee Territory, or as required in order for Licensee to comply with its diligence obligations set forth in Section 5.2 (Development Diligence Obligations) and (b) Manufacture the TAK-385 Licensed Compound and TAK-385 Licensed Products in the Takeda Territory.

  • Exclusive License Licensor hereby grants to Licensee and Licensee hereby accepts from Licensor, upon the terms and conditions herein specified, a sole and exclusive license under the Licensed Patent Rights in the Territory, and in the Field of Use to develop, make, have made, import, have imported, use, offer to sell, sell and otherwise commercialize Licensed Product(s).

  • Research Licenses The Parties shall, and do hereby grant to each other all required licenses (on a non-exclusive, non-sublicenseable, royalty-free, for research and development purposes only basis) in respect of an individual Party’s Intellectual Property necessary for the other Party to conduct the activities contemplated hereunder this Agreement.

  • License Grant Subject to the terms and conditions of this Agreement, including the Retained Rights, Licensor hereby grants to Licensee an exclusive, sublicensable (as provided in Section 2.4 only), non-transferable (except as provided in Section 10.2), royalty-bearing, worldwide license, under the Licensed Patents to make, have made, use, import, sell, and offer for sale Licensed Products solely in the Field, including, for the avoidance of doubt, the right to conduct research and development.

Time is Money Join Law Insider Premium to draft better contracts faster.